BNP Paribas Exane initiated coverage of Sanofi (SNY) with an Outperform rating and $65 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi’s Strong Financial Performance and Promising Growth Prospects Earn a Buy Rating
- Novavax price target lowered to $10 from $12 at BofA
- Sanofi’s Tolebrutinib Shows Promise in Phase 3 Study for Multiple Sclerosis
- Trump plans to announce ‘major’ tariff on pharmaceutical imports, Reuters says
- Sanofi announces publication of tolebrutinib Phase 3 data in NEJM